Worth Nathalie F, Berry Celia L, Thomas Anita C, Campbell Julie H
Centre for Research in Vascular Biology, School of Biomedical Sciences, The University of Queensland, Brisbane, Qld 4072, Australia.
Atherosclerosis. 2005 Nov;183(1):65-73. doi: 10.1016/j.atherosclerosis.2005.02.034. Epub 2005 Jun 9.
To investigate the effect of S18886, a novel TP (thromboxane A2 and prostaglandin endoperoxide) receptor antagonist, on the development of aortic fatty streaks and advanced lesions in a rabbit model of atherosclerosis and restenosis.
The right iliac artery of 96 rabbits (8 groups, n=12/group) was balloon injured, then the animals were fed a cholesterol-enriched diet for 6 weeks. In Groups 1-4, concomitant oral administration of S18886 at 5 mg/kg/day over the 6-week-period reduced the intima to media ratio of lesions in the uninjured aorta and injured iliac artery, the accumulation of macrophages and the expression of ICAM-1 compared with 1 mg/kg/day S18886, 30 mg/kg/day aspirin and placebo, with no effect on body weight or plasma cholesterol levels. In Groups 5-8, 2 weeks of treatment with 5 mg/kg/day S18886 reduced the intima to media ratio of restenosing lesions when pre-formed iliac artery lesions underwent a second balloon injury at week 6. The smaller lesions resulting from S18886 treatment correlated with a significant decrease in the neointimal area occupied by macrophages, as well as in ICAM-1 expression, with no effect on the smooth muscle component. Aspirin treatment had no significant effect on the neointimal smooth muscle component, but partially inhibited macrophage infiltration, without inhibiting ICAM-1 expression.
Inhibition of the TP receptor using S18886 causes a significant decrease in the recruitment of monocyte/macrophages within fatty streaks in the uninjured aorta and within primary and restenosing atherosclerotic lesions in the iliac artery of rabbits. Since TP receptor agonists, such as thromboxane A2, prostanoid endoperoxides and isoprostanes participate in vessel wall inflammation and are localized and increased in atherosclerotic plaques, treatment with S18886 may enhance atherosclerotic lesion stability by attenuating inflammatory processes that ultimately lead to plaque rupture.
研究新型血栓素A2和前列腺素内过氧化物(TP)受体拮抗剂S18886对动脉粥样硬化和再狭窄兔模型中主动脉脂肪条纹和晚期病变发展的影响。
对96只兔子(8组,每组n = 12只)的右髂动脉进行球囊损伤,然后给动物喂食富含胆固醇的饮食6周。在第1 - 4组中,在6周期间每天口服5 mg/kg的S18886,与每天1 mg/kg的S18886、30 mg/kg/天的阿司匹林和安慰剂相比,可降低未损伤主动脉和损伤髂动脉中病变的内膜与中膜比值、巨噬细胞的积聚以及细胞间黏附分子-1(ICAM-1)的表达,对体重或血浆胆固醇水平无影响。在第5 - 8组中,当在第6周对预先形成的髂动脉病变进行第二次球囊损伤时,每天5 mg/kg的S18886治疗2周可降低再狭窄病变的内膜与中膜比值。S18886治疗导致较小的病变与巨噬细胞占据的新生内膜面积以及ICAM-1表达的显著降低相关,对平滑肌成分无影响。阿司匹林治疗对新生内膜平滑肌成分无显著影响,但部分抑制巨噬细胞浸润,而不抑制ICAM-1表达。
使用S18886抑制TP受体可使未损伤主动脉脂肪条纹内以及兔髂动脉原发性和再狭窄动脉粥样硬化病变内的单核细胞/巨噬细胞募集显著减少。由于TP受体激动剂,如血栓素A2、前列腺素内过氧化物和异前列腺素参与血管壁炎症并在动脉粥样硬化斑块中定位并增加,用S18886治疗可能通过减弱最终导致斑块破裂的炎症过程来增强动脉粥样硬化病变稳定性。